NFKB1 and non-small cell lung carcinoma: Previous studies presented that QNZ, a NF-κB inhibitor, reduced NSCLC cell invasion and the protein expression of MMP-9, VEGF, MCL-1, C-FLIP and XIAP through NF-κB inactivation (17, 30).